|

Liver Disease Clinical Trials in Portland, OR

18 recruiting studies within 50 miles

Phase
Trial Phase Dist.
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine TumorsPhase 2<1 mi
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT TrialPhase 3<1 mi
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 CirrhosisPhase 2<1 mi
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency EmphysemaPhase 2<1 mi
DBS TaT in Peer-assisted Telemedicine for Hepatitis CN/A<1 mi
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic DisordersPhase 2<1 mi
Long-term Safety and Efficacy of Odevixibat in Patients With Alagille SyndromePhase 3<1 mi
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)Phase 2<1 mi
Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)—<1 mi
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or LymphomaPhase 3<1 mi
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid TumorsPhase 2<1 mi
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry—<1 mi
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE TrialPhase 1/2<1 mi
T-Cell Therapy (ECT204) in Adults With Advanced HCCPhase 1/2<1 mi
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and ChemotherapyPhase 3<1 mi
A Study of Novel Study Interventions and Combinations in Participants With Colorectal CancerPhase 2<1 mi
A Study of MGC026 in Participants With Advanced Solid TumorsPhase 1<1 mi
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid TumorsPhase 1<1 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.